nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—prostate cancer	0.385	1	CbGaD
Rasagiline—BCL2—Docetaxel—prostate cancer	0.217	0.688	CbGbCtD
Rasagiline—CYP1A2—Flutamide—prostate cancer	0.0343	0.108	CbGbCtD
Rasagiline—CYP1A2—Estrone—prostate cancer	0.0248	0.0784	CbGbCtD
Rasagiline—CYP1A2—Conjugated Estrogens—prostate cancer	0.0162	0.0513	CbGbCtD
Rasagiline—CYP1A2—Estradiol—prostate cancer	0.0142	0.045	CbGbCtD
Rasagiline—CYP1A2—Etoposide—prostate cancer	0.00929	0.0294	CbGbCtD
Rasagiline—BCL2—prostate gland—prostate cancer	0.00348	0.157	CbGeAlD
Rasagiline—CYP1A2—urine—prostate cancer	0.00287	0.13	CbGeAlD
Rasagiline—BCL2—epithelium—prostate cancer	0.00255	0.115	CbGeAlD
Rasagiline—BCL2—renal system—prostate cancer	0.00237	0.107	CbGeAlD
Rasagiline—BCL2—Fulvestrant—Estradiol—prostate cancer	0.00208	1	CbGdCrCtD
Rasagiline—BCL2—bone marrow—prostate cancer	0.00179	0.0809	CbGeAlD
Rasagiline—BCL2—testis—prostate cancer	0.00153	0.0692	CbGeAlD
Rasagiline—MAOB—prostate gland—prostate cancer	0.00145	0.0654	CbGeAlD
Rasagiline—MAOB—seminal vesicle—prostate cancer	0.00122	0.0553	CbGeAlD
Rasagiline—BCL2—lymph node—prostate cancer	0.00111	0.0502	CbGeAlD
Rasagiline—MAOB—renal system—prostate cancer	0.000987	0.0446	CbGeAlD
Rasagiline—MAOB—urethra—prostate cancer	0.000969	0.0438	CbGeAlD
Rasagiline—CYP1A2—renal system—prostate cancer	0.000702	0.0317	CbGeAlD
Rasagiline—MAOB—testis—prostate cancer	0.000638	0.0288	CbGeAlD
Rasagiline—MAOB—lymph node—prostate cancer	0.000462	0.0209	CbGeAlD
Rasagiline—Shock—Capecitabine—prostate cancer	2.74e-05	0.000164	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—prostate cancer	2.73e-05	0.000164	CcSEcCtD
Rasagiline—Body temperature increased—Etoposide—prostate cancer	2.73e-05	0.000164	CcSEcCtD
Rasagiline—Abdominal pain—Etoposide—prostate cancer	2.73e-05	0.000164	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—prostate cancer	2.73e-05	0.000164	CcSEcCtD
Rasagiline—Nervous system disorder—Capecitabine—prostate cancer	2.73e-05	0.000163	CcSEcCtD
Rasagiline—Vertigo—Prednisone—prostate cancer	2.73e-05	0.000163	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—prostate cancer	2.73e-05	0.000163	CcSEcCtD
Rasagiline—Syncope—Prednisone—prostate cancer	2.72e-05	0.000163	CcSEcCtD
Rasagiline—Hypoaesthesia—Epirubicin—prostate cancer	2.71e-05	0.000162	CcSEcCtD
Rasagiline—Skin disorder—Capecitabine—prostate cancer	2.7e-05	0.000162	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—prostate cancer	2.7e-05	0.000161	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—prostate cancer	2.69e-05	0.000161	CcSEcCtD
Rasagiline—Hyperhidrosis—Capecitabine—prostate cancer	2.69e-05	0.000161	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—prostate cancer	2.69e-05	0.000161	CcSEcCtD
Rasagiline—Hypotension—Docetaxel—prostate cancer	2.68e-05	0.000161	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—prostate cancer	2.68e-05	0.00016	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—prostate cancer	2.68e-05	0.00016	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—prostate cancer	2.67e-05	0.00016	CcSEcCtD
Rasagiline—Loss of consciousness—Prednisone—prostate cancer	2.67e-05	0.00016	CcSEcCtD
Rasagiline—Epistaxis—Doxorubicin—prostate cancer	2.65e-05	0.000159	CcSEcCtD
Rasagiline—Anorexia—Capecitabine—prostate cancer	2.65e-05	0.000159	CcSEcCtD
Rasagiline—Nausea—Estradiol—prostate cancer	2.65e-05	0.000159	CcSEcCtD
Rasagiline—Vomiting—Mitoxantrone—prostate cancer	2.64e-05	0.000158	CcSEcCtD
Rasagiline—Convulsion—Prednisone—prostate cancer	2.63e-05	0.000157	CcSEcCtD
Rasagiline—Hypertension—Prednisone—prostate cancer	2.62e-05	0.000157	CcSEcCtD
Rasagiline—Rash—Mitoxantrone—prostate cancer	2.62e-05	0.000157	CcSEcCtD
Rasagiline—Dermatitis—Mitoxantrone—prostate cancer	2.62e-05	0.000157	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.62e-05	0.000157	CcSEcCtD
Rasagiline—Headache—Mitoxantrone—prostate cancer	2.6e-05	0.000156	CcSEcCtD
Rasagiline—Hypotension—Capecitabine—prostate cancer	2.6e-05	0.000156	CcSEcCtD
Rasagiline—Insomnia—Docetaxel—prostate cancer	2.6e-05	0.000156	CcSEcCtD
Rasagiline—Arthralgia—Prednisone—prostate cancer	2.58e-05	0.000155	CcSEcCtD
Rasagiline—Paraesthesia—Docetaxel—prostate cancer	2.58e-05	0.000154	CcSEcCtD
Rasagiline—Anxiety—Prednisone—prostate cancer	2.58e-05	0.000154	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.57e-05	0.000154	CcSEcCtD
Rasagiline—Dyspnoea—Docetaxel—prostate cancer	2.56e-05	0.000153	CcSEcCtD
Rasagiline—Somnolence—Docetaxel—prostate cancer	2.55e-05	0.000153	CcSEcCtD
Rasagiline—Discomfort—Prednisone—prostate cancer	2.55e-05	0.000153	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—prostate cancer	2.55e-05	0.000153	CcSEcCtD
Rasagiline—Hypersensitivity—Etoposide—prostate cancer	2.55e-05	0.000152	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—prostate cancer	2.54e-05	0.000152	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.53e-05	0.000152	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—prostate cancer	2.53e-05	0.000152	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—prostate cancer	2.53e-05	0.000151	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—prostate cancer	2.53e-05	0.000151	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—prostate cancer	2.52e-05	0.000151	CcSEcCtD
Rasagiline—Insomnia—Capecitabine—prostate cancer	2.52e-05	0.000151	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—prostate cancer	2.51e-05	0.00015	CcSEcCtD
Rasagiline—Paraesthesia—Capecitabine—prostate cancer	2.5e-05	0.00015	CcSEcCtD
Rasagiline—Decreased appetite—Docetaxel—prostate cancer	2.5e-05	0.00015	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—prostate cancer	2.49e-05	0.000149	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—prostate cancer	2.49e-05	0.000149	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—prostate cancer	2.48e-05	0.000148	CcSEcCtD
Rasagiline—Asthenia—Etoposide—prostate cancer	2.48e-05	0.000148	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—prostate cancer	2.48e-05	0.000148	CcSEcCtD
Rasagiline—Dyspnoea—Capecitabine—prostate cancer	2.48e-05	0.000148	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—prostate cancer	2.47e-05	0.000148	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—prostate cancer	2.47e-05	0.000148	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—prostate cancer	2.47e-05	0.000148	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—prostate cancer	2.46e-05	0.000147	CcSEcCtD
Rasagiline—Infection—Prednisone—prostate cancer	2.46e-05	0.000147	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—prostate cancer	2.46e-05	0.000147	CcSEcCtD
Rasagiline—Constipation—Docetaxel—prostate cancer	2.46e-05	0.000147	CcSEcCtD
Rasagiline—Dyspepsia—Capecitabine—prostate cancer	2.45e-05	0.000147	CcSEcCtD
Rasagiline—Chills—Epirubicin—prostate cancer	2.45e-05	0.000147	CcSEcCtD
Rasagiline—Pruritus—Etoposide—prostate cancer	2.45e-05	0.000146	CcSEcCtD
Rasagiline—Shock—Prednisone—prostate cancer	2.44e-05	0.000146	CcSEcCtD
Rasagiline—Nervous system disorder—Prednisone—prostate cancer	2.43e-05	0.000145	CcSEcCtD
Rasagiline—Decreased appetite—Capecitabine—prostate cancer	2.42e-05	0.000145	CcSEcCtD
Rasagiline—Alopecia—Epirubicin—prostate cancer	2.41e-05	0.000144	CcSEcCtD
Rasagiline—Skin disorder—Prednisone—prostate cancer	2.41e-05	0.000144	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Capecitabine—prostate cancer	2.4e-05	0.000144	CcSEcCtD
Rasagiline—Hyperhidrosis—Prednisone—prostate cancer	2.4e-05	0.000143	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—prostate cancer	2.39e-05	0.000143	CcSEcCtD
Rasagiline—Constipation—Capecitabine—prostate cancer	2.38e-05	0.000142	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—prostate cancer	2.37e-05	0.000142	CcSEcCtD
Rasagiline—Feeling abnormal—Docetaxel—prostate cancer	2.37e-05	0.000142	CcSEcCtD
Rasagiline—Diarrhoea—Etoposide—prostate cancer	2.37e-05	0.000142	CcSEcCtD
Rasagiline—Anorexia—Prednisone—prostate cancer	2.36e-05	0.000141	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—prostate cancer	2.36e-05	0.000141	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—prostate cancer	2.35e-05	0.000141	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—prostate cancer	2.34e-05	0.00014	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—prostate cancer	2.34e-05	0.00014	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—prostate cancer	2.33e-05	0.000139	CcSEcCtD
Rasagiline—Back pain—Epirubicin—prostate cancer	2.3e-05	0.000137	CcSEcCtD
Rasagiline—Feeling abnormal—Capecitabine—prostate cancer	2.29e-05	0.000137	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—prostate cancer	2.29e-05	0.000137	CcSEcCtD
Rasagiline—Dizziness—Etoposide—prostate cancer	2.29e-05	0.000137	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—prostate cancer	2.28e-05	0.000137	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—prostate cancer	2.28e-05	0.000136	CcSEcCtD
Rasagiline—Gastrointestinal pain—Capecitabine—prostate cancer	2.27e-05	0.000136	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—prostate cancer	2.27e-05	0.000136	CcSEcCtD
Rasagiline—Abdominal pain—Docetaxel—prostate cancer	2.27e-05	0.000136	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—prostate cancer	2.27e-05	0.000136	CcSEcCtD
Rasagiline—Chills—Doxorubicin—prostate cancer	2.26e-05	0.000136	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Prednisone—prostate cancer	2.26e-05	0.000135	CcSEcCtD
Rasagiline—Insomnia—Prednisone—prostate cancer	2.24e-05	0.000134	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—prostate cancer	2.23e-05	0.000134	CcSEcCtD
Rasagiline—Paraesthesia—Prednisone—prostate cancer	2.22e-05	0.000133	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—prostate cancer	2.21e-05	0.000132	CcSEcCtD
Rasagiline—Urticaria—Capecitabine—prostate cancer	2.21e-05	0.000132	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—prostate cancer	2.2e-05	0.000132	CcSEcCtD
Rasagiline—Body temperature increased—Capecitabine—prostate cancer	2.2e-05	0.000132	CcSEcCtD
Rasagiline—Abdominal pain—Capecitabine—prostate cancer	2.2e-05	0.000132	CcSEcCtD
Rasagiline—Vomiting—Etoposide—prostate cancer	2.2e-05	0.000132	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—prostate cancer	2.2e-05	0.000132	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—prostate cancer	2.19e-05	0.000131	CcSEcCtD
Rasagiline—Agitation—Epirubicin—prostate cancer	2.18e-05	0.000131	CcSEcCtD
Rasagiline—Dyspepsia—Prednisone—prostate cancer	2.18e-05	0.000131	CcSEcCtD
Rasagiline—Rash—Etoposide—prostate cancer	2.18e-05	0.00013	CcSEcCtD
Rasagiline—Dermatitis—Etoposide—prostate cancer	2.18e-05	0.00013	CcSEcCtD
Rasagiline—Headache—Etoposide—prostate cancer	2.17e-05	0.00013	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—prostate cancer	2.16e-05	0.00013	CcSEcCtD
Rasagiline—Decreased appetite—Prednisone—prostate cancer	2.15e-05	0.000129	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—prostate cancer	2.15e-05	0.000129	CcSEcCtD
Rasagiline—Malaise—Epirubicin—prostate cancer	2.14e-05	0.000128	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—prostate cancer	2.13e-05	0.000128	CcSEcCtD
Rasagiline—Syncope—Epirubicin—prostate cancer	2.13e-05	0.000127	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—prostate cancer	2.13e-05	0.000127	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—prostate cancer	2.13e-05	0.000127	CcSEcCtD
Rasagiline—Constipation—Prednisone—prostate cancer	2.12e-05	0.000127	CcSEcCtD
Rasagiline—Hypersensitivity—Docetaxel—prostate cancer	2.12e-05	0.000127	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—prostate cancer	2.11e-05	0.000126	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—prostate cancer	2.09e-05	0.000125	CcSEcCtD
Rasagiline—Cough—Epirubicin—prostate cancer	2.07e-05	0.000124	CcSEcCtD
Rasagiline—Asthenia—Docetaxel—prostate cancer	2.06e-05	0.000123	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—prostate cancer	2.06e-05	0.000123	CcSEcCtD
Rasagiline—Nausea—Etoposide—prostate cancer	2.05e-05	0.000123	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—prostate cancer	2.05e-05	0.000123	CcSEcCtD
Rasagiline—Hypersensitivity—Capecitabine—prostate cancer	2.05e-05	0.000123	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisone—prostate cancer	2.04e-05	0.000122	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—prostate cancer	2.04e-05	0.000122	CcSEcCtD
Rasagiline—Pruritus—Docetaxel—prostate cancer	2.03e-05	0.000122	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—prostate cancer	2.03e-05	0.000122	CcSEcCtD
Rasagiline—Gastrointestinal pain—Prednisone—prostate cancer	2.03e-05	0.000121	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—prostate cancer	2.02e-05	0.000121	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—prostate cancer	2.02e-05	0.000121	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—prostate cancer	2.02e-05	0.000121	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—prostate cancer	2.01e-05	0.000121	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.01e-05	0.00012	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—prostate cancer	2e-05	0.00012	CcSEcCtD
Rasagiline—Asthenia—Capecitabine—prostate cancer	2e-05	0.000119	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—prostate cancer	1.98e-05	0.000119	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—prostate cancer	1.98e-05	0.000118	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Urticaria—Prednisone—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Pruritus—Capecitabine—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Diarrhoea—Docetaxel—prostate cancer	1.97e-05	0.000118	CcSEcCtD
Rasagiline—Abdominal pain—Prednisone—prostate cancer	1.96e-05	0.000117	CcSEcCtD
Rasagiline—Body temperature increased—Prednisone—prostate cancer	1.96e-05	0.000117	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—prostate cancer	1.95e-05	0.000117	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—prostate cancer	1.93e-05	0.000116	CcSEcCtD
Rasagiline—Infection—Epirubicin—prostate cancer	1.93e-05	0.000115	CcSEcCtD
Rasagiline—Cough—Doxorubicin—prostate cancer	1.92e-05	0.000115	CcSEcCtD
Rasagiline—Shock—Epirubicin—prostate cancer	1.91e-05	0.000114	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—prostate cancer	1.9e-05	0.000114	CcSEcCtD
Rasagiline—Diarrhoea—Capecitabine—prostate cancer	1.9e-05	0.000114	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—prostate cancer	1.9e-05	0.000114	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—prostate cancer	1.9e-05	0.000114	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—prostate cancer	1.9e-05	0.000114	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—prostate cancer	1.88e-05	0.000113	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—prostate cancer	1.87e-05	0.000112	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—prostate cancer	1.87e-05	0.000112	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—prostate cancer	1.87e-05	0.000112	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—prostate cancer	1.86e-05	0.000112	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.86e-05	0.000111	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—prostate cancer	1.85e-05	0.000111	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—prostate cancer	1.85e-05	0.000111	CcSEcCtD
Rasagiline—Dizziness—Capecitabine—prostate cancer	1.84e-05	0.00011	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—prostate cancer	1.83e-05	0.00011	CcSEcCtD
Rasagiline—Vomiting—Docetaxel—prostate cancer	1.83e-05	0.000109	CcSEcCtD
Rasagiline—Hypersensitivity—Prednisone—prostate cancer	1.83e-05	0.000109	CcSEcCtD
Rasagiline—Rash—Docetaxel—prostate cancer	1.81e-05	0.000108	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—prostate cancer	1.81e-05	0.000108	CcSEcCtD
Rasagiline—Dermatitis—Docetaxel—prostate cancer	1.81e-05	0.000108	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—prostate cancer	1.81e-05	0.000108	CcSEcCtD
Rasagiline—Headache—Docetaxel—prostate cancer	1.8e-05	0.000108	CcSEcCtD
Rasagiline—Infection—Doxorubicin—prostate cancer	1.78e-05	0.000107	CcSEcCtD
Rasagiline—Asthenia—Prednisone—prostate cancer	1.78e-05	0.000106	CcSEcCtD
Rasagiline—Vomiting—Capecitabine—prostate cancer	1.77e-05	0.000106	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.77e-05	0.000106	CcSEcCtD
Rasagiline—Shock—Doxorubicin—prostate cancer	1.76e-05	0.000106	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—prostate cancer	1.76e-05	0.000105	CcSEcCtD
Rasagiline—Rash—Capecitabine—prostate cancer	1.75e-05	0.000105	CcSEcCtD
Rasagiline—Pruritus—Prednisone—prostate cancer	1.75e-05	0.000105	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—prostate cancer	1.75e-05	0.000105	CcSEcCtD
Rasagiline—Dermatitis—Capecitabine—prostate cancer	1.75e-05	0.000105	CcSEcCtD
Rasagiline—Headache—Capecitabine—prostate cancer	1.74e-05	0.000104	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—prostate cancer	1.74e-05	0.000104	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—prostate cancer	1.74e-05	0.000104	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—prostate cancer	1.73e-05	0.000104	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—prostate cancer	1.73e-05	0.000103	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—prostate cancer	1.72e-05	0.000103	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—prostate cancer	1.71e-05	0.000102	CcSEcCtD
Rasagiline—Nausea—Docetaxel—prostate cancer	1.71e-05	0.000102	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—prostate cancer	1.71e-05	0.000102	CcSEcCtD
Rasagiline—Diarrhoea—Prednisone—prostate cancer	1.7e-05	0.000101	CcSEcCtD
Rasagiline—Decreased appetite—Epirubicin—prostate cancer	1.68e-05	0.000101	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—prostate cancer	1.68e-05	0.0001	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—prostate cancer	1.68e-05	0.000156	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2A6—prostate cancer	1.67e-05	0.000156	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Epirubicin—prostate cancer	1.67e-05	0.0001	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—GSK3B—prostate cancer	1.66e-05	0.000155	CbGpPWpGaD
Rasagiline—Constipation—Epirubicin—prostate cancer	1.66e-05	9.92e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—RXRA—prostate cancer	1.66e-05	0.000155	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	1.66e-05	0.000155	CbGpPWpGaD
Rasagiline—Nausea—Capecitabine—prostate cancer	1.65e-05	9.89e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—EGR1—prostate cancer	1.64e-05	0.000153	CbGpPWpGaD
Rasagiline—Dizziness—Prednisone—prostate cancer	1.64e-05	9.81e-05	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.63e-05	9.78e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PRKCQ—prostate cancer	1.63e-05	0.000152	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKR1C3—prostate cancer	1.63e-05	0.000152	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—prostate cancer	1.62e-05	9.71e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—PRKACB—prostate cancer	1.62e-05	0.000151	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAP3K7—prostate cancer	1.61e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	1.61e-05	0.00015	CbGpPWpGaD
Rasagiline—Paraesthesia—Doxorubicin—prostate cancer	1.61e-05	9.64e-05	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—prostate cancer	1.6e-05	0.00015	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP17A1—prostate cancer	1.6e-05	0.00015	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CREBBP—prostate cancer	1.6e-05	0.000149	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—prostate cancer	1.6e-05	9.57e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—prostate cancer	1.6e-05	9.56e-05	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.6e-05	0.000149	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—COMT—prostate cancer	1.6e-05	0.000149	CbGpPWpGaD
Rasagiline—Somnolence—Doxorubicin—prostate cancer	1.59e-05	9.54e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—prostate cancer	1.59e-05	0.000148	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Epirubicin—prostate cancer	1.58e-05	9.49e-05	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—prostate cancer	1.58e-05	0.000148	CbGpPWpGaD
Rasagiline—Dyspepsia—Doxorubicin—prostate cancer	1.58e-05	9.45e-05	CcSEcCtD
Rasagiline—Vomiting—Prednisone—prostate cancer	1.58e-05	9.43e-05	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—COMT—prostate cancer	1.57e-05	0.000147	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	1.57e-05	0.000146	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—prostate cancer	1.57e-05	0.000146	CbGpPWpGaD
Rasagiline—Rash—Prednisone—prostate cancer	1.56e-05	9.35e-05	CcSEcCtD
Rasagiline—Dermatitis—Prednisone—prostate cancer	1.56e-05	9.34e-05	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—prostate cancer	1.56e-05	9.33e-05	CcSEcCtD
Rasagiline—Headache—Prednisone—prostate cancer	1.55e-05	9.29e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FGF10—prostate cancer	1.55e-05	0.000145	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.55e-05	9.27e-05	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—prostate cancer	1.54e-05	9.22e-05	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—prostate cancer	1.53e-05	9.18e-05	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—prostate cancer	1.53e-05	9.17e-05	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—prostate cancer	1.53e-05	9.17e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAP2K1—prostate cancer	1.53e-05	0.000143	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOA2—prostate cancer	1.53e-05	0.000143	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CD—prostate cancer	1.52e-05	0.000142	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	1.5e-05	0.00014	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	1.5e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Immune System—VAV3—prostate cancer	1.5e-05	0.00014	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—prostate cancer	1.48e-05	8.85e-05	CcSEcCtD
Rasagiline—Nausea—Prednisone—prostate cancer	1.47e-05	8.81e-05	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—prostate cancer	1.47e-05	8.78e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—prostate cancer	1.46e-05	0.000136	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC5A5—prostate cancer	1.46e-05	0.000136	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGF2—prostate cancer	1.45e-05	0.000136	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITPR1—prostate cancer	1.45e-05	0.000135	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—prostate cancer	1.44e-05	0.000134	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—prostate cancer	1.43e-05	8.55e-05	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—prostate cancer	1.42e-05	8.53e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP2E1—prostate cancer	1.42e-05	0.000133	CbGpPWpGaD
Rasagiline—Body temperature increased—Doxorubicin—prostate cancer	1.42e-05	8.49e-05	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—prostate cancer	1.42e-05	8.49e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—NQO1—prostate cancer	1.41e-05	0.000131	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—JAK2—prostate cancer	1.39e-05	0.00013	CbGpPWpGaD
Rasagiline—Asthenia—Epirubicin—prostate cancer	1.39e-05	8.32e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—TH—prostate cancer	1.39e-05	0.000129	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP1A1—prostate cancer	1.38e-05	0.000129	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP3A4—prostate cancer	1.37e-05	0.000128	CbGpPWpGaD
Rasagiline—Pruritus—Epirubicin—prostate cancer	1.37e-05	8.21e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—HAO1—prostate cancer	1.37e-05	0.000127	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1A1—prostate cancer	1.36e-05	0.000127	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MDM2—prostate cancer	1.36e-05	0.000127	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL18—prostate cancer	1.36e-05	0.000127	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1B1—prostate cancer	1.35e-05	0.000126	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—prostate cancer	1.34e-05	0.000125	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—prostate cancer	1.33e-05	7.94e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CB—prostate cancer	1.32e-05	0.000124	CbGpPWpGaD
Rasagiline—Hypersensitivity—Doxorubicin—prostate cancer	1.32e-05	7.91e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PDGFRB—prostate cancer	1.32e-05	0.000123	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GGT1—prostate cancer	1.31e-05	0.000122	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOA1—prostate cancer	1.29e-05	0.00012	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—prostate cancer	1.29e-05	7.7e-05	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—prostate cancer	1.28e-05	7.67e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	1.27e-05	0.000119	CbGpPWpGaD
Rasagiline—Pruritus—Doxorubicin—prostate cancer	1.27e-05	7.59e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP19A1—prostate cancer	1.27e-05	0.000118	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB3—prostate cancer	1.25e-05	0.000116	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGFR2—prostate cancer	1.24e-05	0.000116	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1B—prostate cancer	1.24e-05	0.000116	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—prostate cancer	1.23e-05	7.38e-05	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—prostate cancer	1.23e-05	7.34e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—RXRA—prostate cancer	1.22e-05	0.000114	CbGpPWpGaD
Rasagiline—Rash—Epirubicin—prostate cancer	1.22e-05	7.31e-05	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—prostate cancer	1.22e-05	7.31e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	1.22e-05	0.000114	CbGpPWpGaD
Rasagiline—Headache—Epirubicin—prostate cancer	1.21e-05	7.27e-05	CcSEcCtD
Rasagiline—Dizziness—Doxorubicin—prostate cancer	1.19e-05	7.1e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—COMT—prostate cancer	1.18e-05	0.00011	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	1.17e-05	0.00011	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTP1—prostate cancer	1.17e-05	0.00011	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTNNB1—prostate cancer	1.17e-05	0.00011	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ITPR1—prostate cancer	1.15e-05	0.000108	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—prostate cancer	1.15e-05	6.89e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1A—prostate cancer	1.15e-05	0.000107	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—prostate cancer	1.15e-05	0.000107	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—prostate cancer	1.14e-05	0.000107	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—prostate cancer	1.14e-05	6.83e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	1.13e-05	0.000106	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—prostate cancer	1.13e-05	6.77e-05	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—prostate cancer	1.13e-05	6.76e-05	CcSEcCtD
Rasagiline—Headache—Doxorubicin—prostate cancer	1.12e-05	6.72e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—PSAT1—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CBR1—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADI1—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TST—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CSAD—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GRHL1—prostate cancer	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR4—prostate cancer	1.09e-05	0.000102	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMS—prostate cancer	1.09e-05	0.000102	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EP300—prostate cancer	1.09e-05	0.000102	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	1.09e-05	0.000102	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTM1—prostate cancer	1.08e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	1.07e-05	9.96e-05	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—prostate cancer	1.07e-05	6.38e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—prostate cancer	1.06e-05	9.9e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—LPL—prostate cancer	1.06e-05	9.88e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ICAM1—prostate cancer	1.05e-05	9.77e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BAD—prostate cancer	1.04e-05	9.7e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGT2B17—prostate cancer	1.03e-05	9.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CKMT2—prostate cancer	1.03e-05	9.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGT2B15—prostate cancer	1.03e-05	9.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GRHPR—prostate cancer	1.03e-05	9.66e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1A1—prostate cancer	1.02e-05	9.54e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ERCC2—prostate cancer	1.01e-05	9.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	1.01e-05	9.44e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—MED12—prostate cancer	9.95e-06	9.29e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGF—prostate cancer	9.95e-06	9.28e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRS1—prostate cancer	9.95e-06	9.28e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PGAM2—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MBTPS1—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAGLU—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SULT2B1—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AOX1—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM3—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RFK—prostate cancer	9.73e-06	9.08e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—GSK3B—prostate cancer	9.66e-06	9.01e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MTHFR—prostate cancer	9.53e-06	8.89e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	9.51e-06	8.87e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARA—prostate cancer	9.35e-06	8.73e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CREBBP—prostate cancer	9.33e-06	8.71e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—prostate cancer	9.3e-06	8.68e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—prostate cancer	9.26e-06	8.64e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP3A43—prostate cancer	9.22e-06	8.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AMACR—prostate cancer	9.22e-06	8.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SRD5A2—prostate cancer	9.22e-06	8.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT1—prostate cancer	9.22e-06	8.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—DEGS1—prostate cancer	9.22e-06	8.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	9.07e-06	8.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	9.01e-06	8.41e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAP2K1—prostate cancer	8.9e-06	8.31e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—prostate cancer	8.85e-06	8.25e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSD17B1—prostate cancer	8.8e-06	8.21e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	8.8e-06	8.21e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAV1—prostate cancer	8.79e-06	8.2e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—prostate cancer	8.78e-06	8.2e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGF2—prostate cancer	8.47e-06	7.9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	8.46e-06	7.9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	8.42e-06	7.85e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	8.33e-06	7.77e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JAK2—prostate cancer	8.12e-06	7.58e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—prostate cancer	8.07e-06	7.53e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—prostate cancer	8.01e-06	7.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	7.94e-06	7.41e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MDM2—prostate cancer	7.92e-06	7.4e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—B4GALT4—prostate cancer	7.84e-06	7.32e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGD—prostate cancer	7.84e-06	7.32e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—prostate cancer	7.81e-06	7.29e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—prostate cancer	7.71e-06	7.19e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—INS—prostate cancer	7.58e-06	7.07e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CREBBP—prostate cancer	7.43e-06	6.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TNFRSF21—prostate cancer	7.37e-06	6.88e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—prostate cancer	7.24e-06	6.75e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTAP—prostate cancer	7.17e-06	6.69e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP7B1—prostate cancer	7.17e-06	6.69e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—prostate cancer	7.15e-06	6.67e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—prostate cancer	7.08e-06	6.61e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—prostate cancer	7.04e-06	6.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	7.01e-06	6.54e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SULT1E1—prostate cancer	6.99e-06	6.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SRD5A1—prostate cancer	6.99e-06	6.52e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—prostate cancer	6.84e-06	6.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	6.79e-06	6.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	6.69e-06	6.24e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—prostate cancer	6.68e-06	6.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSD17B3—prostate cancer	6.67e-06	6.22e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACSL4—prostate cancer	6.67e-06	6.22e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—prostate cancer	6.66e-06	6.22e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NOS3—prostate cancer	6.65e-06	6.2e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—prostate cancer	6.59e-06	6.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	6.59e-06	6.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PHGDH—prostate cancer	6.39e-06	5.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ARG2—prostate cancer	6.39e-06	5.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UMPS—prostate cancer	6.39e-06	5.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	6.36e-06	5.94e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—prostate cancer	6.35e-06	5.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—LDHB—prostate cancer	6.27e-06	5.85e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—prostate cancer	6.18e-06	5.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP3A5—prostate cancer	6.15e-06	5.74e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—prostate cancer	6.14e-06	5.73e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—prostate cancer	6.08e-06	5.67e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—prostate cancer	5.96e-06	5.56e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PDHA1—prostate cancer	5.94e-06	5.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UCP3—prostate cancer	5.94e-06	5.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TCN2—prostate cancer	5.94e-06	5.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA3—prostate cancer	5.94e-06	5.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC22A3—prostate cancer	5.67e-06	5.29e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSD3B1—prostate cancer	5.67e-06	5.29e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	5.5e-06	5.13e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA4—prostate cancer	5.44e-06	5.07e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TBXAS1—prostate cancer	5.44e-06	5.07e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—prostate cancer	5.42e-06	5.05e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	5.31e-06	4.96e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—prostate cancer	5.3e-06	4.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA2—prostate cancer	5.3e-06	4.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCG5—prostate cancer	5.23e-06	4.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SULT1A1—prostate cancer	5.23e-06	4.88e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—prostate cancer	5.12e-06	4.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA1—prostate cancer	5.11e-06	4.77e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—prostate cancer	5.06e-06	4.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT2—prostate cancer	5.05e-06	4.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSD3B2—prostate cancer	5.05e-06	4.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTO1—prostate cancer	5.05e-06	4.72e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	4.86e-06	4.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—LRP2—prostate cancer	4.85e-06	4.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLCB2—prostate cancer	4.85e-06	4.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2C18—prostate cancer	4.85e-06	4.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—P4HB—prostate cancer	4.75e-06	4.43e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—prostate cancer	4.7e-06	4.39e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC22A1—prostate cancer	4.62e-06	4.31e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.57e-06	4.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SULT2A1—prostate cancer	4.5e-06	4.2e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MED12—prostate cancer	4.43e-06	4.14e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GNG5—prostate cancer	4.4e-06	4.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA3—prostate cancer	4.24e-06	3.95e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—prostate cancer	4.16e-06	3.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.16e-06	3.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGDS—prostate cancer	4.04e-06	3.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2C19—prostate cancer	4.01e-06	3.75e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—prostate cancer	3.92e-06	3.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACHE—prostate cancer	3.92e-06	3.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2A6—prostate cancer	3.87e-06	3.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.86e-06	3.6e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—prostate cancer	3.84e-06	3.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1C3—prostate cancer	3.77e-06	3.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PRKACB—prostate cancer	3.75e-06	3.5e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—prostate cancer	3.74e-06	3.49e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP17A1—prostate cancer	3.71e-06	3.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.66e-06	3.41e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA2—prostate cancer	3.53e-06	3.3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—prostate cancer	3.37e-06	3.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2E1—prostate cancer	3.29e-06	3.07e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NQO1—prostate cancer	3.26e-06	3.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TH—prostate cancer	3.21e-06	3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.19e-06	2.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP3A4—prostate cancer	3.18e-06	2.96e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.16e-06	2.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1B1—prostate cancer	3.12e-06	2.91e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—prostate cancer	3.06e-06	2.85e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GGT1—prostate cancer	3.02e-06	2.82e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA1—prostate cancer	2.98e-06	2.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP19A1—prostate cancer	2.94e-06	2.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RXRA—prostate cancer	2.83e-06	2.64e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.76e-06	2.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—COMT—prostate cancer	2.73e-06	2.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—prostate cancer	2.72e-06	2.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ITPR1—prostate cancer	2.67e-06	2.49e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.63e-06	2.45e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—prostate cancer	2.53e-06	2.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—prostate cancer	2.5e-06	2.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—LPL—prostate cancer	2.45e-06	2.29e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.37e-06	2.21e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ERCC2—prostate cancer	2.35e-06	2.19e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—prostate cancer	2.21e-06	2.06e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARA—prostate cancer	2.16e-06	2.02e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAV1—prostate cancer	2.03e-06	1.9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.94e-06	1.81e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.85e-06	1.73e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—INS—prostate cancer	1.75e-06	1.64e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CREBBP—prostate cancer	1.72e-06	1.6e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.63e-06	1.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NOS3—prostate cancer	1.54e-06	1.44e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.42e-06	1.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—prostate cancer	1.41e-06	1.31e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—prostate cancer	1.23e-06	1.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—prostate cancer	1.17e-06	1.09e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—prostate cancer	8.66e-07	8.08e-06	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—prostate cancer	7.07e-07	6.6e-06	CbGpPWpGaD
